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Abstract
Introduction. Triple-negative breast cancer (TNBC), representing over 15% of all breast cancers, has a poorer 
prognosis than other subtypes. There is no effective targeted treatment available for the TNBC sufferers. Ribo-
somal S6 kinases (RSKs) have been previously proposed as drug targets for TNBC based on observations that 
85% of these tumors express activated RSKs.
Materials and methods. Herein we examined an involvement of RSK1 (p90 ribosomal S6 kinase 1) in a regu-
lation of TNBC growth and metastatic spread in an animal model, which closely imitates human disease. Mice 
were inoculated into mammary fat pad with 4T1 cells or their RSK1-depleted variant. We examined tumor 
growth and formation of pulmonary metastasis. Boyden chamber, wound healing and soft agarose assays were 
performed to evaluate cells invasion, migration and anchorage-independent growth. 
Results. We found that RSK1 promoted tumor growth and metastasis in vivo. After 35 days all animals inocu-
lated with control cells developed tumors while in the group injected with RSK1-negative cells, there were 75% 
tumor-bearing mice. Average tumor mass was estimated as 1.16 g and 0.37 g for RSK1-positive vs. -negative 
samples, respectively (p < 0.0001). Quantification of the macroscopic pulmonary metastases indicated that mice 
with RSK1-negative tumors developed approximately 85% less metastatic foci on the lung surface (p < 0.001). 
This has been supported by in vitro data presenting that RSK1 promoted anchorage-independent cell growth 
and migration. Moreover, RSK1 knock-down corresponded with decreased expression of cell cycle regulating 
proteins, i.e. cyclin D3, CDK6 and CDK4. 
Conclusions. We provide evidence that RSK1 supports tumor growth and metastatic spread in vivo as well as 
in vitro migration and survival in non-adherent conditions. Further studies of RSK1 involvement in TNBC pro-
gression may substantiate our findings, laying the foundations for development of anti-RSK1-based therapeutic 
strategies in the management of patients with TNBC. (Folia Histochemica et Cytobiologica 2018, Vol. 56, No. 1, 
11–20)
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Triple-negative breast cancer (TNBC), defined by 
the lack of estrogen and progesterone receptors 
(ER, PR) as well as HER2 expression, represents 
approximately 15–20% of all breast cancers [1]. 
TNBC shows more aggressive clinical behavior with 
a high probability of local and distant metastases 
[2, 3]. The majority of deaths take place within the 
first 5 years from initial diagnosis [4]. There is still 
no effective target-specific therapy for patients with 
TNBC and current regimens are based mainly on 
conventional chemotherapy (e.g. anthracyclines, 
taxanes, and platinum agents) [1, 5]. Therefore, 
better knowledge of TNBC biology and identifica-
tion of prognostic markers is an important clinical 
challenge.
Members of the 90 kDa ribosomal S6 kinase 
(RSK) family of proteins regulate key cellular process-
es, such as migration, proliferation and survival [6]. 
Structurally, all four RSK isoforms (RSK1-4) share 
73–80% homology and their functional domains are 
highly-conserved. Despite these similarities, RSK1-4 
may play various roles and their function appears to 
be cell-type specific [6, 7] since differences in their 
activation by upstream signaling and expression/sub-
cellular localization patterns of individual RSKs as 
well as their specific preferences for substrates were 
reported [7]. We have previously demonstrated that 
FGF2/FGFR2 signaling activated RSK2 and that this 
pathway promoted in vitro anchorage-independent 
growth and migration of mammary epithelial and 
breast cancer cells [8]. Furthermore, we revealed 
RSK2-FGFR2 co-expression in breast cancer tissue 
and showed that patients with tumors expressing 
active RSK (RSK-P) alone or in combination with 
FGFR2 had worse disease-free survival [9]. Indeed, 
most studies show that RSK2 promotes cancer pro-
gression, whereas the role of RSK1 seems to be more 
controversial as it was shown to have both anti- and 
pro-metastatic effects depending on the cancer type 
[6, 7]. Smith et al. reported that both RSK1 and RSK2 
expression was elevated in approximately 50% of all 
breast tumors comparing to non-transformed tissues 
[10]. Genome-wide mRNA analysis of mammary 
epithelial cells revealed that RSK1 and RSK2 were 
major pro-migratory effectors of ERK/MEK pathway 
[11]. Accordingly, Smolen and colleagues demon-
strated that RSK1 silencing prevented MCF10A cell 
migration in vitro [12]. Similar effect was observed 
in melanoma cells, where RSK1 overexpression in-
fluenced actomyosin stability resulting in increased 
cell motility [13]. In contrast, RSK1 decreased A549 
lung cancer cells migration in vitro and their meta-
static potential in a zebrafish model. Additionally, 
low RSK1 expression in primary tumors was shown 
to correlate with increased number of metastases in 
lung cancer patients [14]. Finally, RSK1 (contrary to 
RSK2) knock-down in head and neck squamous cell 
carcinoma (HNSCC) cells did not influence invasive-
ness at all [15].
Despite the continuous research in the field, 
functions of the RSK isoforms are still not well under-
stood. Several authors have suggested that RSK1 plays 
an important role in TNBC, in particular in regulating 
cell motility and invasiveness [16–18]; however, the 
significance of RSK1 for the regulation of TNBC 
metastasis has never been investigated. Therefore, we 
examined for the first time an involvement of RSK1 
in the regulation of TNBC growth and progression 
in an animal model which exhibits similar metastatic 
pattern to that of human disease.
Materials and methods
Cell culture and reagents. Murine triple-negative breast 
cancer 4T1 cell line was obtained from ATCC. Cells were 
grown at 37°C in a humidified atmosphere of 5% CO2 in 
DMEM supplemented with 10% fetal bovine serum (FBS) 
and penicillin/streptomycin (100 U/mL/100 μg/mL). Media 
and their supplements were purchased from Sigma-Aldrich 
(St. Louis, Missouri, USA). RIPA Buffer 10X (#9806) and 
the following antibodies were obtained from Cell Signal-
ing Technology (Danvers, MA, USA): anti-Akt (#9272), 
anti-Akt-Ser473 (#4058), anti-Bax (#5023), anti-Bcl-xl 
(#2762), anti-cyclin D1 (#2978), anti-cyclin D3 (#2936), 
anti-CDK2 (#2546), anti-CDK4 (#12790), anti-CDK6 
(#3136), anti-cytokeratin 7 (#4465), anti-cytokeratin 17 
(#4543), anti-cytokeratin 8/18 (#4546), anti-cytokeratin 
18 (#4548), anti-cytokeratin 19 (#4558), anti-Pan-keratin 
(#4545), anti-E-cadherin (#14472), anti-ERK1/2 (#4695), 
anti-ERK1/2-Thr202/Tyr204 (#9101), anti-FAK (#3285), 
anti-FAK-Tyr397 (#3283), anti-p38 (#9212), anti-p38- 
-Thr180/Tyr182 (#9211), anti-RSK1 (#8408), anti-RSK2 
(#5528), anti-SAPK/JNK-Thr183/Tyr185 (#9251) anti-Src 
(#2108) and anti-Src-Tyr416 (#2101). Antibodies against 
Bcl-2 (M0887) were from Dako (Glostrup, Denmark). Anti-
bodies anti-b-actin (A5316), anti-vimentin (V6389) and low 
gelling temperature agarose (A9414) were obtained from 
Sigma-Aldrich. Goat anti-rabbit (926-68021) and Donkey 
anti-mouse (926-32212) IRDye secondary antibodies were 
purchased from LI-COR Biosciences (Lincoln, NE, USA).
Establishment of RSK1 knock-down. 4T1 RSK1-negative 
cell line was generated with lentiviral system based on 
pLKO.1-TRC vector (Addgene, Cambridge, Massachusetts, 
USA, #10878) with cloned shRNA designed on the basis 
of the following DNA sequence: 5’- CCC AAC ATC ATC 
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ACT CTG AAA -3’ [19]. 4T1 CTRL cell line was transfected 
with pLKO.1 backbone plasmid and used as a control. Trans-
fection was done using TurboFect Transfection Reagent 
(Thermo Scientific, Waltham, MA, USA) according to the 
manufacturer’s protocol. Stable cell line expressing shRNA 
was established by puromycin selection. RSK1 knock-down 
efficiency was verified by Western blotting.
Animal experiments. BALB/c mice (5-week-old females) 
were purchased from and maintained in the Tri-City 
Academic Laboratory Animal Centre — Research and 
Services Centre of the Medical University of Gdansk, 
Poland. Animals were maintained on a regular light-dark 
cycle at 22 ± 2°C and provided with freely available food 
and water. 105 cells in 50 μl of phosphate-buffered saline 
(PBS) were injected into mammary fat pad. 12 mice received 
RSK1-negative cells while the control group (N = 12) was 
injected with control, RSK1-positive cells. Growing tumors 
were measured every three days by digital caliper starting 
on day 8 after cancer cells transplantation. After sacrificing 
the animals by cervical dislocation on day 35 primary tumors 
were removed, measured and weighted. Their volume was 
calculated with the formula of an ellipsoid (length × width 
× height × 0.5236) [20]. Lungs were collected and visually 
examined for the number of macrometastases by two inves-
tigators independently [21, 22]. This study was conducted in 
accordance with the Local Ethics Committee of the Medical 
University of Gdansk, Poland (permission number: 46/2015, 
obtained 26/10/2015).
Western blotting. Cells grown up to 80–90% of confluency 
were lysed with 2 × concentrated Laemmli buffer containing 
2 mM PMSF, 10 μg/ml aprotinin, 10 μg/ml leupeptin, 5 mM 
EGTA, 1 mM EDTA, 2 mM Na4P2O7, 5 mM NaF and 5 mM 
Na3VO4. Tissue specimens were homogenized with MagNA 
Lyser (Roche, Basel, Switzerland) and lysed in 1× RIPA 
buffer supplemented with all inhibitors. Samples with equal 
amounts of protein per lane (at the range of 20–30 μg) were 
resolved by SDS polyacrylamide gel electrophoresis (SDS- 
-PAGE) and transferred onto nitrocellulose membrane. The 
membranes were incubated for 1 h in 5% skimmed milk in 
TBST and probed with specific antibodies overnight at 4°C 
followed by 1 h incubation with IRDye secondary antibodies. 
Specific protein bands were visualized with Odyssey® CLx 
Imaging System (LI-COR Biosciences) according to the 
manufacturer’s protocol.
Soft agarose assay for anchorage-independent growth. Soft 
agarose assay was performed as described before [8, 23]. 
Briefly, 104 cells per well of 6-well plate were suspended in 
3 ml of 0.5% low gelling temperature agarose prepared in 
DMEM (10% FBS) and overlaid on 3 ml solidified 0.6% 
bottom layer of agarose. The top layer was covered with 
3 ml of DMEM (10% FBS) refreshed every 2–3 days. After 
10 days of culture colonies were counted and measured 
using PrimoVert microscope (Carl Zeiss, Jena, Germany) 
and ImageJ software developed at the National Institutes 
of Health (Bethesda, MD, USA).
Migration assay. 4T1 cells were detached using Cell Disso-
ciation Solution (Millipore, Billerica, MA, USA). The 5 × 
105 cell were suspended in serum-free DMEM and placed 
in the inner compartment of Boyden chamber inserts with 
polycarbonate membranes (8-μm pores, BD Biosciences, 
Franklin Lakes, NJ, USA), pre-coated with 50 μl Matrigel 
Matrix Growth Factor Reduced (BD Biosciences) diluted 
1:100 with serum-free media. Cells were allowed to migrate 
toward DMEM containing 10% FBS. After 24 h non-migrat-
ed cells were removed by cotton swab. Nuclei of migrated 
cells were stained with DAPI and counted using a AxioVert 
200 microscope (Carl Zeiss). Ten to twenty random fields 
per membrane were photographed and analyzed in each 
experiment.
Wound healing assay. 4T1 cells were plated in a 6-cm culture 
dish and incubated at 37°C. The following day scratches were 
made by scraping confluent monolayers with a sterile pipette 
tip in the center of the dish. Next, the cells were washed twice 
with PBS and incubated overnight in serum-free media. 
Subsequently, media containing 10% FBS was added to 
initiate cell motility. To measure the migration capacities, 
images were captured at the beginning of the experiment 
and 6 h after wounding. The wound closure was evaluated 
using ImageJ software.
Proliferation assay. Proliferation tests were performed 
using WST-1 reagent (Roche) in accordance with manufac-
turer’s protocol. Briefly, 4T1 control and RSK1-negative 
cells were cultured in 96-well microplates. After 96 h WST-1 
was added to the cells and incubated for next 4 h. Cell 
viability was determined by the absorbance measurement 
at 440 nm. 
Statistical analyses. All data are expressed as means ± SD 
from at least three independent experiments. Comparative 
data were analyzed with Mann-Whitney U test using the 
Statistica 10.0 software (Statsoft, Cracow, Poland). The 
results were considered statistically significant when p value 
was lower than 0.05.
RESULTS
RSK1 promotes primary tumor growth  
and lung metastasis in vivo
To investigate the functional significance of RSK1 
expression in breast cancer growth and metastasis, 
we generated stable knock-down of RSK1 in 4T1 
cell line using a pLKO.1-TRC vector expressing spe-
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cific shRNA sequence targeting RSK1 (designed on 
previously published siRNA [19], shown to lack any 
off-target effects). A significant reduction in RSK1 
protein level as compared to the control (transfect-
ed with pLKO.1 backbone plasmid) was shown by 
Western blotting (Fig. 1A). RSK1 knock-down did 
not induce any phenotypic changes in 2-dimensional 
culture and RSK1-negative variant exhibited the same 
proliferation rate in vitro as 4T1 control cells (Fig. 2). 
Both 4T1 variants i.e. control and RSK1-negative were 
orthotopically implanted into mammary fat pads of 
BALB/c mice. Tumors were palpable 6–10 days after 
cell inoculation. Stability of RSK1 knock-down was 
confirmed in tumors resected after 35 days from the 
primary sites (Fig. 1B). The depletion of RSK1 led to 
a significant reduction in primary tumor growth. All 
Figure 1. RSK1 promotes tumor growth in vivo. A. Stable knock-down of RSK1 in 4T1 cells. B. RSK1 expression in tumors 
resected at the 35th day of growth. Cells were injected into mammary fat pads of BALB/c mice. C. All animals injected with 
wild-type 4T1 cells (N = 12) developed tumors while in the second group (N = 12) injected with RSK1-negative cells there 
were only 9 tumor-bearing mice. D. Average tumor mass was 1.16 g ± 0.36 and 0.37 g ± 0.22 for control and RSK1-neg-
ative tumors respectively, ***p < 0.0001. E. Tumor size was measured every three days starting on day 8 after cancer cell 
implantation. The volumes of tumors were calculated using the formula of an ellipsoid (length × width × height × 0.5236). 
***p < 0.0001 refers to statistical analysis for the last measurement, on 34th day). Each square represents individual tumor. 
Straight lines represent the average value for each group.
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mice in control group (N = 12) developed tumors, 
while in the second group (N = 12) that contained 
animals injected with RSK1-negative cells there were 
only 9 tumor-bearing animals (Fig. 1C). Overall tumor 
size and mass were lower in the RSK1-depleted cohort 
compared to the control with average value of 0.37 g 
and 1.16 g, respectively (p < 0.0001) (Fig. 1D–E). 
As expected from the above data, RSK1 knock-down 
affected formation of distant metastases. 58% of 
the animals transplanted with RSK1-negative cells 
displayed colonization in lungs compared to 100% 
of the mice in the control group. Quantification of 
the macroscopic pulmonary metastases (as described 
previously in [21, 22, 24]) indicated that RSK1-deplet-
ed cohort developed an average 2.83 metastatic foci 
on the lung surface compared with 18.25 foci in the 
control cohort (p < 0.001) (Fig. 3A–B).
RSK1 increases migration in vitro
To investigate in vitro the functional consequences 
of RSK1 depletion in 4T1 cells, we assessed their po-
tential to grow in anchorage-independent conditions. 
4T1 CTRL and RSK1-negative cells were cultured 
in soft-agarose for 10 days. RSK1 silencing reduced 
size of the colonies (which reflects proliferation rate 
in anchorage-independent conditions) by nearly 40% 
(p < 0.001) and its clonogenic potential by approximate-
ly 60% (p < 0.0001) (Fig. 4A–C). To determine if RSK1 
knock-down affects 4T1 cell motility and invasion, the 
Boyden chamber migration assay and wound healing test 
were performed. As shown in Figure 5A–B, silencing of 
RSK1 reduced trans-well migration of 4T1 RSK1 cells by 
nearly 50% (p < 0.0001). Migration rates were also eval-
uated by measuring the distance between edges of the 
“wound”. Six hours after scratching, 4T1 RSK1-negative 
cells showed significantly reduced migration abilities. 
On the contrary, 4T1 CTRL cells almost completely 
healed up, covering approximately 70% of the “wound” 
width comparing to the 40% in RSK1-depleted cells 
(p < 0.05) (Fig. 5C–D). 
Figure 2. Proliferation rates of 4T1 CTRL and RSK1-negative 
cells. The values presented are means ± SD (N = 3), p = 
= 0.98. After 96 h of growth WST-1 reagent was added to the 
cells and incubated for next 4 h. Cell viability was determined 
by the absorbance measurement at 440 nm.
Figure 3. RSK1 promotes pulmonary metastasis. A. Lungs 
were resected 35 days after cancer cells injection into mam-
mary fat pads. Representative examples of the macroscopic 
metastatic foci (arrows) on the lung surface of mice bearing 
RSK1-positive (upper panel) and RSK1-negative mammary 
tumors (lower panel). B. Quantification of the macroscopic 
pulmonary metastases indicated that mice with RSK1-neg-
ative tumors developed on average 2.83 (± 4.73) metastatic 
foci on the lung surface compared with 18.25 (± 17.68) foci 
in the group with control tumors. Each square represents 
individual mice. Straight lines represent the average value 
for each group, **p < 0.001.
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RSK1 regulates Src activity and expression of cell 
cycle regulating proteins
To define molecular mechanism of RSK1 role in 
breast cancer progression, we analyzed a panel of sig-
naling molecules that play a critical role in controlling 
growth, apoptosis and cell migration. Western blotting 
analysis revealed no convincing RSK1-dependent 
differences in the level of the activation of pro-pro-
liferative kinases such as Akt, p38, ERK1/2 or SAPK/ 
/JNK (Fig. 6A). However, RSK1 knock-down corre-
sponded with decreased Src activity. Furthermore, in 
4T1 RSK1-negative cells, we observed a significant 
decrease in the level of cell cycle regulating proteins: 
cyclin D3 and CDK6 accompanied with a reduction 
of CDK4 expression (p < 0.05), without changes 
in cyclin D1 and CDK2 expression (Fig. 6A–B). In 
addition, RSK1 silencing had no effect on the ex-
pression of proteins involved in apoptosis (Bcl-2, Bax, 
Bcl-Xl) (Fig. 6A). There was also no change in the 
expression of cytokeratins (CK7, CK8, CK17, CK18, 
CK19) and epithelial-mesenchymal transition (EMT) 
markers (E-cadherin, vimentin) (Fig. 6A). Therefore, 
we conclude that Src kinase seems to be involved in 
RSK1-dependent cell motility, whereas cyclin D3 may 
be engaged in RSK1-mediated cell growth.
Discussion
Murine 4T1 triple-negative breast cancer cells closely 
imitate human disease when inoculated into mamma-
ry fat pad. Moreover, unlike most of the in vivo breast 
cancer models, 4T1 cells can spontaneously metasta-
size from the primary site to lungs, bones, brain and 
liver with a frequency analogous to human disease 
[25]. Therefore we chose 4T1 cell line to investigate 
for the first time the involvement of RSK1 in the 
TNBC development and metastasis and found that 
RSK1 promoted primary tumor growth. Depletion 
of RSK1 resulted in over three times smaller tumors 
and strongly decreased number of metastatic foci on 
the lung surface. 
Several studies have already implied that RSK1 
plays an important role in breast cancer, in particular 
emphasizing its function in regulating cell motility [11, 
12]. Stratford et al. concluded that RSK1 and RSK2 
are key activators of a transcription factor YB-1 in 
human TNBC. They found the EGFR > RSK1/2 > 
> YB-1 pathway as the main driver of TNBC which 
is thought to contribute to cells aggressive behavior 
[16]. These results are in line with a study showing that 
RSK1 and RSK2 promoted the TNBC cells (MDA-
-MB-231 cell line) metastatic spread to liver in vivo. 
Silencing of RSK1 reduced the number of metastatic 
foci to the similar extend as shown in our study. Fur-
thermore, the level of activated RSKs was higher in 
TNBC tumors than in non-transformed mammary 
tissue [18]. Additionally, it was demonstrated that 
growth and migration of MDA-MB-231 TNBC cells, 
contrary to ER/PR-positive MCF7 cells, depended on 
both RSK1 and RSK2 activity [26]. RSKs have been 
previously proposed as drug targets for TNBC based 
on observations that 85% of these tumors expressed 
Figure 4. RSK1 promotes anchorage-independent growth 
of 4T1 cells in vitro. A. 4T1 cells growth in soft agarose. 
Microphotographs were taken after 10 days of culture. 
B. Measurement of colonies volume was done with ImageJ 
software. RSK1 knock-down in 4T1 cells reduced colony vol-
ume by nearly 40%, **p < 0.001. C. The average percentage 
of colonies formed in soft agarose, ***p < 0.0001. The values 
presented are means ± SD (N = 3).
17RSK1 promotes TNBC growth and metastasis
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2018
10.5603/FHC.a2018.0001
www.fhc.viamedica.pl
activated RSKs [17]. There are also reports suggest-
ing that RSK1 behaves as a tumor suppressor. Zhao 
et al. demonstrated that level of RSK1 was lower in 
breast cancer tumors compared to adjacent tissue. 
RSK1 mRNA expression was inversely correlated with 
tumor size, stage and metastasis to nodes. In addition 
patients with decreased RSK1 transcript had shorter 
DFS and OS. Surprisingly, the same study showed that 
selective RSK inhibitor SL0101 decreased invasion of 
MDA-MB-231 TNBC cells [27]. Taking into account 
this and our data it would be interesting to stratify 
patient cohorts into individual subtypes and examine 
prognostic significance of RSK1 for TNBC women. 
Resistance to anchorage dependence and ability 
to migrate are hallmarks of metastatic cancers. We 
showed that RSK1 silencing impaired anchorage-in-
dependent growth and motility of 4T1 cells. Our 
findings are partially in line with those of Cuesta and 
Holz, who reported that both RSK1 and RSK2 are 
required for MDA-MB-231 cells growth in anchor-
age-dependent clonogenic assay. Contrary to our 
observations, individual silencing of RSK1 or RSK2 
did not suppressed cell proliferation, suggesting 
a compensatory role of both isoforms in MDA-MB-231 
cell line what seems to be not relevant for 4T1 cells 
[26]. We also found that RSK1 modulated activity of 
Src kinase shown to promote survival and invasion 
of cancer cells [28]. We believe that decreased Src 
phosphorylation in RSK1-negative 4T1 cells may be 
responsible for their limited metastatic potential. 
In addition, we observed that knock-down of RSK1 
triggered significant reduction of the levels of proteins 
that are involved in cell cycle regulation, i.e. cyclin D3 
and its partner CDK6, accompanied with a reduction 
of CDK4 expression (p < 0.05). This is contrary to the 
findings showing that RSK1 and RSK2 through the 
regulation of translation repressor PDCD4 reduced 
the levels of cyclin D1 and Bcl-2 what consequently 
Figure 5. RSK1 enhances 4T1 cells migration in vitro. A. Representative images of Boyden chamber membranes. Nuclei 
of migrated cells were stained with DAPI. B. 4T1 control and RSK1-negative cells migration rate in Boyden chamber assay, 
***p < 0.0001. C. Representative images from the wound-healing assay taken 0 and 6 h after scratching. D. Bar graphs show-
ing wound closure rates in 4T1 control and RSK1-negative cells *p < 0.05. The values presented are means ± SD (N = 3).
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induced apoptosis in MDA-MB-231 cells [26]. Dis-
crepancies between these results may be explained 
by the fact that Cuesta and Holz used double knock-
down of both isoforms and RSKs pan-inhibitor while 
our study focused specifically on RSK1 silencing. 
This is supported by studies which reported that 
RSK2, but not RSK1, is the key regulator of cyclin 
D1 expression in various cancer cell lines [29, 30]. 
Accordingly to our results, Chi et al. indicated that 
cyclin D3 expression was associated with poor DFS of 
breast cancer patients. Protein and mRNA levels of 
cyclin D3 were up-regulated in both mammary tumors 
and breast cancer cell lines. Furthermore, cyclin D3 
was shown to physically interact with actin in MCF-7 
and MDA-MB-231 cells and enhance breast cancer 
cell migration and invasion in vitro [31]. This may 
Figure 6. Western blotting analysis of control and RSK1-negative 4T1 cells. A. We compared expression and activation of 
indicated proteins involved in proliferation (Akt, p38, ERK1/2, SAPK/JNK, Src), cell cycle regulation (cyclin D1, cyclin D3, 
CDK2, CDK4, CDK6), apoptosis (Bcl-2, Bax, Bcl-Xl), epithelial-to-mesenchymal transition (E-cadherin, vimentin) and 
cytoskeleton formation (CK7, CK8, CK17, CK18, CK19). Experiments were done in triplicates. B. Densitometry analysis of 
selected Western blots presented above. *p < 0.05, **p < 0.001. Analysis was done with ImageJ software.
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explain our observation of decreased D3 expression 
in RSK1-negative 4T1 cells. 4T1 RSK1-negative 
cells displayed decreased expression of cell cycle 
proteins, although their 2D proliferation had not 
been affected. It is known that cyclin expression level 
not always correlates with the proliferation rate. In 
breast cancer patients cyclin D3, a predictor of bet-
ter DFS, displayed no correlation with widely used 
proliferation marker Ki67 [31]. Moreover, Sicinska 
et al. showed that knock-down of cyclin D3 had no 
impact on proliferation of leukemia cell lines [32]. 
Our present results suggest that cyclin D3 is engaged 
only in RSK1-mediated 3-dimensional growth in soft 
agarose growth (but not in 2D growth) of 4T1 cells, 
probably because of an additional pressure cells are 
subjected in anchorage-independent conditions.
To the best of our knowledge, this is the first report 
on RSK1 role in a clinically relevant animal model 
of TNBC. We provide evidence that RSK1 supports 
tumor growth and metastatic spread in vivo as well 
as in vitro migration and survival in non-adherent 
conditions.
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